News

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...
BioWorld2d
Oxford University Innovations divulges new BRD4 degradation inducers
Oxford University Innovations Ltd. has synthesized hypoxia-activated proteolysis targeting chimeras (hypoxia-activated PROTACs; HAP-TAC) comprising a hypoxia-activated moiety modified E3 ubiquitin ...
Taiwan News4d
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
BioWorld6d
Shanghai Helioson Pharmaceutical divulges new GSPT1 degradation inducers
Shanghai Helioson Pharmaceutical Co. Ltd. has synthesized molecular glue degraders comprising an E3 ubiquitin ligase coupled to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A ...